FRI0331 Apremilast for the treatment of behçet's syndrome: a phase ii randomized, placebo-controlled, double-blind studyGülen Hatemi, Yusuf Yazıcı, P. A. Merkel et al.|Annals of the Rheumatic Diseases|2013Cited by 8
SAT0382 Palace 4, A Phase 3, Randomized, Controlled TRIAL of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Treatment of Psoriatic Arthritis: Long-Term (52-WEEK) Improvements in Physical FunctionA. Wells, Jacob Aelion, Christopher J Edwards et al.|Annals of the Rheumatic Diseases|2014Cited by 3
SAT0377 Long-Term Safety and Tolerability of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: A Phase 3, Randomized, Controlled TrialAde Adebajo, Jacob Aelion, R. Stevens et al.|Annals of the Rheumatic Diseases|2014Cited by 2